Sentences with phrase «cell therapy targeted»

This may contribute to the development of stem cell therapy targeted at other diseases.

CAR T - cell therapy targeting B - cell maturation protein may be a new effective type of immunotherapy treatment for patients with multiple myeloma.

Okyanos cardiac cell therapy targets the restoration of blood flow to the heart and repairs damaged heart tissue caused by heart attack or ischemic and non-ischemic heart disease.

CAR T cell therapies targeting CD19 for lymphoma are currently being tested in clinical trials at various institutions:

Not exact matches

The start - up's premiere product, the Thin Ice vest, uses cold therapy to target areas of the body with high concentrations of thermoreceptors, which are nerve cells that are able to detect the presence of hot or cold temperatures.

Gene therapy, for example, frequently involves using a virus to deliver a gene to the cells that scientists are targeting.

I won't reveal yet who my favorites are, but I will say that these young scientist - founders came up with very creative solutions for preventing infections in some common surgeries, tackling resistance in targeted antibody drugs, improving gene vectors for cell therapies, helping the vision - impaired «see» faces and better read their environments, imaging hard - to - see spots in the lungs and other organs, improving genetic risk analysis, and expediting the logistical operations of hospitals.

Cambridge, MA — February 6, 2017 — Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates, announced today that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug application (IND) for the company's lead program, light - activated AU - 011 in ocular melanoma (OM).

Cambridge, MA — December 21, 2017 — Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates, announced today that it closed a $ 30 million Series C financing.

His work indicates that this cell surface marker could serve as a target for a novel brain cancer vaccine or T - cell therapies engineered to recognize and kill tumors carrying that neoantigen.

Cambridge, MA — March 30, 2017 — Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates, announced today that it has enrolled and dosed the first patient in its Phase 1b clinical trial of light - activated AU - 011, an investigational, first - in - class targeted therapy in development for the treatment of ocular melanoma, a rare and life - threatening disease.

What Stephen Hawking Missed: Small Biotechs Developing Promising Cell Therapies for Devastating Disease Source: Streetwise Reports (5/2/18) In the second of a two - part series exploring the disruptive cell therapy space, Maxim Group analyst Jason McCarthy takes a look at small - cap companies targeting big - ticket indications and their potential to drive blockbuster value for both patients and investCell Therapies for Devastating Disease Source: Streetwise Reports (5/2/18) In the second of a two - part series exploring the disruptive cell therapy space, Maxim Group analyst Jason McCarthy takes a look at small - cap companies targeting big - ticket indications and their potential to drive blockbuster value for both patients and investcell therapy space, Maxim Group analyst Jason McCarthy takes a look at small - cap companies targeting big - ticket indications and their potential to drive blockbuster value for both patients and investors.

By targeting the affected cells instead of the virus, the approach could also cut the chances of the virus becoming resistant to the therapy, researchers say.

Unlike conventional chemotherapies and radiation that indiscriminately eradicate fast - growing tissues and ravage people's bodies with side effects, new therapies specifically target tumors using tailored cells from individual patients.

«Current therapies in clinical trials are focused on targeting genetic changes in tumors and helping to boost one's immune system to fight the cancer cells.

All are examples of translational researchers converting molecular knowledge about specific cancer cells into effective, targeted therapies.

By combining this strategy with cancer cell - targeting materials, we should be able to develop a therapy for glioblastoma and other challenging cancers in the future.»

The current study was designed to clarify the cellular hierarchy underlying glioblastoma, to identify epigenetic factors that distinguish glioblastoma stem cells from more differentiated tumor cells and to suggest potential therapies targeting those factors.

«These are optimistic results for one of the first targeted therapies for cancer stem cells,» says Antonio Jimeno, MD, PhD, investigator at the CU Cancer Center, director of the university's Cancer Stem Cell - Directed Clinical Trials Program, and principal investigator of the clinical trial at the CU Cancer Center site.

To address this challenge, our research group is using nanoparticles not only to deliver more chemotherapy drugs to the target site within cancer cells, but also to compromise the function of the efflux pumps and thereby significantly improve safety and efficacy of cancer therapy.»

«Considering that PDPN is associated with poor prognosis in GBM, CAR T - cell therapy that targets this protein is promising for treatment of patients with relapsed or resistant tumors following first - line chemotherapy,» says Toshihiko Wakabayashi, a coauthor and the chair of Department of Neurosurgery Nagoya University School of Medicine.

Investigations aimed at determining the downstream targets of LIF would help to clarify the functional importance of LIF in muscle regeneration, and further its potential application in cell transplantation therapy.»

«Our study reveals a new mechanism that could be harnessed for biological therapies for lupus and other autoimmune diseases, where the immune system mistakenly targets the body's own cells,» says senior study author Boris Reizis, PhD, professor of Pathology and Medicine at NYU Langone.

«This is a first step,» he says, because it provides a target for therapy: somehow stimulating the SVZ to start replenishing the pool of cells that give rise to the vulnerable, depleted interneurons in CHD.

EMD Serono, Kirschbaum says, «focuses on the development of targeted cancer therapies on three therapeutic platforms: targeting the tumor cell, the tumor environment, and the immune system.»

The Mast Cells and Basophiles: Targets for Innovative Therapies project, funded by COST funding BM1007 of the EU, brings together European experts focusing on the identification of new target molecules for drug development, including allergy drugs.

To acquire new insights into the biology and possible therapy of these tumors, Feigin et al. looked for aberrant expression of G protein — coupled receptors, cell signaling proteins that have been successfully targeted for treatment of other disorders such as depression.

Another strategy, which Steinman and others were studying, involves a therapy to target dendritic cells inside the body rather than taking them out and personalizing therapy for each patient.

Researchers at The University of Texas MD Anderson Cancer Center developed a novel chimeric mouse model to test the combination therapy using immune checkpoint blockades with therapies targeting myeloid - derived suppressor cells (MDSCs).

«Now that we know the cell of origin for Barrett's esophagus, the next step is to develop therapies that target these cells or the signaling pathways that are activated by acid reflux,» said Dr. Que.

A new wave of potential immune therapies aims to target the network of complex sugars that coat cancer cells, Esther Landhuis reported in «Cancer's sweet cloak» (SN: 4/1/17, p. 24).

My cancer systems biology team at the University of California, Merced, is tackling diagnosis and treatment of therapy - resistant cancers by elucidating the network of changes within cells as a way to identify new drug targets and circumvent cancer resistance.

While the combination of targeted therapies improves patient outcomes, any remaining cancer cells can lead to drug resistance.

Conventional therapies target rapidly dividing tumor cells, but are unable to eradicate the highly chemoresistant tumor initiating cells (TICs), ultimately responsible for relapse and spreading of the tumors in other parts of the body.

«In order to block tumor recurrence after radiation therapy, we used an antibody to target and inhibit these cancer stem cells,» said Dr. Xu.

Treatment for advanced melanoma has seen success with targeted therapies — drugs that interfere with division and growth of cancer cells by targeting key molecules — especially when multiple drugs are used in combination.

Dwarki and Jaime Escobedo improved the AAV's ability to insert genes into chromosomes by adding a gene promoter region from cytomegalovirus, known to be active in the target for their gene therapy, muscle cells.

The development of targeted therapies has significantly improved the survival of melanoma patients over the last decade; however, patients often relapse because many therapies do not kill all of the tumor cells, and the remaining cells adapt to treatment and become resistant.

«We are looking to optimize the combinations of targeted therapies and the scheduling of those therapies so we can improve tumor shrinkage and minimize potential toxicities for a patient,» said Andrew Aplin, PhD, Associate Director for Basic Research and the Program Leader for Cancer Cell Biology and Signaling (CCBS) in the NCI - designated Sidney Kimmel Cancer Center at Jefferson Health.

However, on page 1391 in this issue, Yun et al. (5) show that high doses of vitamin C selectively kill colorectal cancer cells carrying activating mutations in the oncogenes KRAS or BRAF, which are often refractory to approved targeted therapies.

«Although some non-small cell lung cancer patients have increased benefit of targeted therapy or immunotherapy instead of chemotherapy, for some groups of patients with NSNSCLC, chemotherapy has been the standard treatment for more than 30 years,» Gandhi notes.

The targeted therapy everolimus may be safely combined with R - CHOP for new, untreated diffuse large B - cell lymphoma according to the results of a pilot study by Mayo Clinic researchers published in the Lancet Haematology.

The researchers were able to reverse these epigenetic changes with the use of an FDA - approved drug, forcing the cancer cells out of hiding and potentially making them better targets for the same immune therapy that in the past may have failed.

Based on a report published on August 20, 2015 in Nature Communications, it has been established that certain nutrients support CML stem cell activity in vivo, thus pointing towards a potential therapeutic target for CML therapy.

Chimeric antigen receptor (CAR) T - cell therapies utilize a patient's own T cells that have been genetically engineered to bind to a specific antigen on target cancer cells.

While the disease can take many forms, recent advances have better characterized how lymphoma cells proliferate and interact with other cells and tissues, leading to the development of powerful, targeted therapies with fewer side effects than traditional approaches.

In an effort to expand the number of cancer gene mutations that can be specifically targeted with personalized therapies, researchers at University of California San Diego School of Medicine and Moores Cancer Center looked for combinations of mutated genes and drugs that together kill cancer cells.

Moreover, her studies are the first to indicate that therapies targeted at controlling the properties of smooth muscle cells within lesions may be highly effective in treating a disease that is the leading cause of death worldwide.

A drug approved in Europe to treat osteoporosis has now been shown to stop the growth of breast cancer cells, even in cancers that have become resistant to current targeted therapies, according to a Duke Cancer Institute study.

«Now that we've identified where the replication - competent virus is hiding, we can start work towards targeting these cells with new therapies aimed at fully eliminating HIV from the body,» Associate Professor Palmer concluded.